IBio Analyst Ratings
IBio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/07/2022 | 7.59% | Cantor Fitzgerald | $2.5 → $0.17 | Downgrades | Overweight → Neutral |
| 11/29/2021 | 849.37% | JMP Securities | → $1.5 | Initiates Coverage On | → Outperform |
| 01/22/2021 | 1798.73% | Cantor Fitzgerald | → $3 | Initiates Coverage On | → Overweight |
| 01/21/2021 | 1798.73% | Cantor Fitzgerald | → $3 | Initiates Coverage On | → Overweight |
| 06/26/2020 | 1640.51% | Alliance Global Partners | → $2.75 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2022 年 7 月 10 日 | 7.59% | 坎托·菲茨杰拉德 | 2.5 美元 → 0.17 美元 | 降级 | 超重 → 中性 |
| 11/29/2021 | 849.37% | JMP 证券 | → 1.5 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 1 月 22 日 | 1798.73% | 坎托·菲茨杰拉德 | → 3 美元 | 启动覆盖范围开启 | → 超重 |
| 2021 年 1 月 21 日 | 1798.73% | 坎托·菲茨杰拉德 | → 3 美元 | 启动覆盖范围开启 | → 超重 |
| 06/26/2020 | 1640.51% | 联盟全球合作伙伴 | → 2.75 美元 | 启动覆盖范围开启 | → 购买 |
iBio Questions & Answers
iBio 问题与解答
The latest price target for iBio (AMEX: IBIO) was reported by Cantor Fitzgerald on October 7, 2022. The analyst firm set a price target for $0.17 expecting IBIO to rise to within 12 months (a possible 7.59% upside). 2 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2022年10月7日公布了iBio（美国证券交易所股票代码：IBIO）的最新目标股价。该分析公司将目标股价定为0.17美元，预计IBIO将在12个月内升至12个月内（可能上涨7.59％）。去年有2家分析公司公布了评级。
The latest analyst rating for iBio (AMEX: IBIO) was provided by Cantor Fitzgerald, and iBio downgraded their neutral rating.
坎托·菲茨杰拉德对iBio（美国证券交易所股票代码：IBIO）的最新分析师评级由坎托·菲茨杰拉德提供，iBio下调了中性评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of iBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for iBio was filed on October 7, 2022 so you should expect the next rating to be made available sometime around October 7, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表、与iBio的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。iBio的最新评级是在2022年10月7日发布的，因此您应该预计下一个评级将在2023年10月7日左右公布。
While ratings are subjective and will change, the latest iBio (IBIO) rating was a downgraded with a price target of $2.50 to $0.17. The current price iBio (IBIO) is trading at is $0.16, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的iBio（IBIO）评级已下调，目标股价为2.50美元，至0.17美元。iBio（IBIO）目前的交易价格为0.16美元，超出了分析师的预期区间。